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Summary Inhaled corticosteroids for asthma treatment have become mainstay of
therapy for patients with persistent asthma. Numerous inhaled corticosteroids are
available but to date no prospective cost-effectiveness studies have been reported
using exclusively US patients and costs. The purpose of this study was to examine the
cost-effectiveness of HFA-beclomethasone (QVARt) compared to CFC-beclometha-
sone (Vancerilt) using data from a year-long prospective randomized, open label,
parallel multicenter trial. Eligibility criteria required patients to have been on a
stable dose of CFC-BDP prior to enrollment. Patients were randomized to either HFA-
BDP at approximately half their previous daily dose of CFC-BDP or to continue CFC-
BDP. Effectiveness data, in terms of symptom-free days (SFDs), were used in a cost-
effectiveness analysis conducted from the viewpoint of managed care. Patients
receiving HFA-BDP reported a greater increase (median¼ 22.1) in the number of SFDs
than those receiving CFC-BDP (median¼ 14.3) (P ¼ 0:03). Total costs of care were less
for patients taking HFA-BDP (median¼ $668) compared to CFC-BDP (median¼ $977).
The median incremental cost-effectiveness ratio was $5.77 (95% CI:$68.08 to
$4.08). The results of this analysis indicate that HFA-BDP was a dominant therapy
(more effective, less costly) compared to CFC-BDP.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
The cost of asthma in the US has been estimated to
be $10.7 billion in 1994, with a majority of the cost
attributable to direct medical care, such as
medications, hospitalizations, and physician visits.1
As the cost of asthma care continues to grow,
physicians, managed care organizations (MCOs),
and other health care entities need economic and
clinical data to make informed decisions about
adopting new medical technologies and treat-
ments. The most recent US guidelines have raised
awareness concerning the role of various pharma-
cological therapies and trigger avoidance.2 Within
the context of these guidelines, the use of inhaled
cortiocosteroids (ICS) has a prominent role in the
management of persistent asthma.
Use of ICS has been shown to be economically
advantageous. For example, use of ICS in Sweden
was associated with a decline in the number of
hospitalizations, resulting in a benefit:cost ratio of
1.5:1.3 More recently, Ozminkowski et al. found
that use of ICS were associated with lower total
medical costs compared to no ICS use for persons
with asthma.4 In the past several years numerous
economic evaluations have compared various ICS
based upon short duration clinical trials.5–13
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Although these studies evaluate a number of
commonly used ICS, none of these economic
analyses were conducted using treatment patterns
and cost estimates from the US.
Patterns of medical care are known to vary
widely by geographical area within the US, and
translation of economic results from other coun-
tries is often difficult. Therefore, it is necessary to
evaluate ICS in terms of their clinical and corre-
sponding economic benefits using data on treat-
ment patterns and cost of resources most similar to
the decision maker’s situation.
Studies that have prospectively examined the
cost-effectiveness of ICS have been conducted
using cost data from other countries, with the
results often reported in terms of US dollars after
applying an currency exchange rate. These two
issues decrease the applicability of the results from
these studies from a US perspective. Hence, the
purpose of this study was to examine the cost-
effectiveness of HFA-beclomethasone (QVARs, 3M
Pharmaceuticals, St. Paul, MN) compared to CFC-
beclomethasone (Vancerils Schering-Plough, Kenil-
worth, NJ) based upon US patients only enrolled in
a multi-center trial. The clinical results of the
study for all patients (US and non-US) have been
reported previously.14
Methods
A cost-effectiveness analysis was conducted using
data from a year-long prospective randomized,
open label, parallel multicenter trial for which the
clinical results have previously been reported.14
The primary purpose was to assess the long-term
effectiveness and safety of switching asthma
patients on a stable dose of CFC-BDP to HFA-BDP
at approximately half their previous daily dose of
CFC-BDP. Patients were randomized in a 3:1 ratio of
HFA-BDP to CFC-BDP and were evaluated at base-
line and 2, 4, 8, and 12 months. Patients kept
diaries of PEF; asthma symptoms (wheeze, cough,
shortness of breath, and chest tightness); sleep
disturbance; and short-acting beta-agonist use. The
trial was approved by local IRBs and patients signed
informed consent.
Measure of effectiveness
The measure of effectiveness was symptom-free
day (SFD),15 defined as a day with the absence of
asthma symptoms.16 Patients recorded asthma
symptoms over a 2 week period prior to randomiza-
tion, from day 1 to end of month 2 (60 days), from
month 7 to month 8 (approximately 30 days), and
from month 11 to month 12 (approximately 30
days). Results from each period, except the first 60
days, were extrapolated to the preceding time-
frame. An intention to treat analysis was used.
Resource utilization and costs
The economic analysis conducted in this study was
a cost-effectiveness analysis conducted from the
perspective of a MCO. Data from asthma exacer-
bations included oral corticosteroids use, hospita-
lizations, and urgent medical care visits were
included in the analysis, but routine physician were
not. Costs were obtained from a large Western US
MCO with over 1 million enrollees. An urgent care
visit was assumed to be billed using Common
Procedural Terminology (CPT) code 99213. This
CPT code was the most frequent code associated
with ICD-9-CM diagnosis of 493. The median cost
was $55.00 (mean¼ $56.39, 95% confidence inter-
vals (CI): $54.86–$57.92). The median cost of a
hospitalization was $1045 (95% CI: $951–$1149).
The median cost for a emergency department (ED)
visit was $466 (95% CI: $443–$489). The primary
analysis assumed that urgent care visits were
treated in physician offices.
Asthma and asthma-related medications used
during the study were included in the cost analysis.
Asthma-related medications included antihista-
mines, cough and cold products, nasal steroids,
antibiotics, oral pharyngeal antifungal prepara-
tions, oral corticosteroids, and pain medications
for sinus and allergy symptoms. Asthma medica-
tions were defined as short acting beta agonists,
cromolyn sodium, nedocromil sodium, theophylline
and leukotriene modifiers.
Medication costs were calculated using average
wholesale price (September 2001). When a generic
version was available, the average price per unit
for that strength of the medications across all
generic manufacturers and package sizes was used.
For single source brand medications, the average
price per unit of branded medications across all
package sizes was used. In the situation of multi-
dose packages, such as nasal steroids, the amount
of drug consumed was calculated using patient
reported dose, frequency, and start/stop dates.
This was then used to determine how many
package units would be necessary over the duration
of the study. This cost determination was per-
formed by a pharmacist blinded to patient group
assignment. The cost of CFC-BDP was estimated
using the brand name Vancerils ($0.2193 per
inhalation). The primary analysis assumed that
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the 80 mg (ex-value) strength of HFA-BDP was used
($0.5204 per inhalation). The cost per patient was
calculated based upon the number of inhalations
necessary to obtain the required dose. Sensitivity
analyses were conducted using the dosing from
40 mg (ex-value) HFA-BDP ($0.4132 per inhalation).
Because the duration of the study was 12 months,
discounting was not performed. Cost-effectiveness
ratios were calculated by dividing the median
number of SFDs into the median total asthma costs
(sum of inhaled corticosteroid costs, asthma-
related medications, urgent care visits and hospi-
talizations) and 95% confidence intervals around
the incremental cost-effectiveness ratio were
determined using Fieller’s Theorem.17 Sensitivity
analyses were conducted to test the robustness of
the results.
Comparisons between groups were conducted
using parametric and non-parametric inferential
statistics. Continuous data were examined to assess
the degree of conformity to assumptions of normal
distribution and equal variance between groups.
Both cost and effectiveness (SFDs) data were found
be skewed, and thus non-parametric statistical
tests were used (Wilcoxon rank sum). For those
variables not normally distributed median values
were reported as well as mean and standard
deviation.
Results
A total of 291 patients were enrolled in the trial at
US sites and had complete data; 218 were
randomized to HFA-BDP and 73 were to continue
CFC-BDP. The rate of study completion was similar
between groups with 85.3% (186) of patients
receiving HFA-BDP and 82.2% (60) for those on
CFC-BDP completing the study (P ¼ 0:52). The most
common reasons for withdrawal were personal
reasons (12 patients, 4.1%), non-compliance with
study protocol (10 patients, 3.4%) and lost to
follow-up (7 patients, 2.4%).
Demographics
Patient demographics are presented in Table 1.
There were more females than males enrolled in
the study for both study groups, but no differences
between groups (P ¼ 0:96). For patients rando-
mized to HFA-BDP, 154 (70.0%) had never used
tobacco compared to 50 (68.5%) of patients
continuing CFC-BDP (P ¼ 0:24). The average age
was 36.3 and 35.4 for patients receiving HFA-BDP
and CFC-BDP, respectively (P ¼ 0:59).
Lung function and symptom-free days
Table 2 displays the change in percent predicted
forced expiratory volume in 1 second (FEV1) from
baseline to end of study for both groups. The two
groups demonstrated similar lung functioning at
baseline (P ¼ 0:90) and change from baseline to
end of study (P ¼ 0:14). The mean percent pre-
dicted FEV1 at baseline was 85.3% (95% CI: 83.3–
87.4%) for patients randomized to HFA-BDP and
85.5% (95% CI: 82.4–88.6%) for CFC-BDP. FEV1 at the
end of study was 87.3% (95% CI: 85.2–89.5%) and
86.0% (95% CI: 82.7–89.2%) for HFA- and CFC-BDP,
respectively. Figure 1 displays the median number
of SFDs at baseline and 12 months for both groups.
No differences were observed between groups at
baseline in the median number of SFDs (P ¼ 0:37).
There was a significantly greater change from
baseline to end of study in the median number of
SFDs for patients on HFA-BDP compared to CFC-BDP
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Table 1 Patient demographics.
Item HFA-BDP (N ¼ 218) CFC-BDP (N ¼ 73) P-value
N % N %
Gender
Females 153 70.2 51 70.0
Males 65 29.8 22 30.0 0.96
Tobacco use
Never 153 70.2 50 68.5
Current 3 1.4 4 5.5
Past 62 28.4 19 26.0 0.24
Age
Mean (SD) 36.4 (13.4) 35.4 (13.1) 0.58
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(22.1 for HFA-BDP and 14.3 for CFC-BDP) (P ¼ 0:03).
The annualized median SFDs was 163.9 for patients
randomized to receive HFA-BDP compared to 110.3
SFDs for those patients taking CFC-BDP. The
absolute median difference was 53.6 days, repre-
senting a difference of 49% between the two
products.
Resource utilization
The percentage of patients requiring oral steroid
bursts was 17.4% (38) for HFA-BDP and 21.9% (16)
for CFC-BDP (Table 3) (P ¼ 0:40). A total of 4
patients, 2 in each group, had three or more short
courses of oral steroids for asthma exacerbations
during the study.
One patient receiving HFA-BDP was hospitalized
for an asthma exacerbation during the study, but
this utilization was not statistically significant
between treatment groups (P ¼ 0:57). Over 90% of
the patients in the study did not have an asthma-
related urgent care physician visit and there was no
difference between groups (P ¼ 0:74).
Costs
Costs associated with resource utilization are
shown in Table 4. The median cost of the study
inhaled corticosteroids were $379.89 for patients
taking HFA-BDP compared to $640.35 for those
randomized to continue CFC-BDP (Po0:001). The
cost of concomitant medications was similar be-
tween the two groups with median costs being
$189.72 for patients receiving HFA-BDP and $237.45
for patients continuing CFC-BDP (P ¼ 0:83). Due to
the low frequency of urgent care visits, the median
cost for both groups was zero (P ¼ 0:74). Similar
findings were observed for hospitalizations
(P ¼ 0:57). Median total costs were significantly
less for patients receiving HFA-BDP ($667.68)
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Figure 1 Median percentage of SFDs from baseline to 12 months.
Table 2 Change in lung function and symptom-free days.
HFA-BDP CFC-BDP P-value
Median Mean [SD] Median Mean [SD]
FEV1(% predicted)
n 1.35 2.0 [9.8] 0.0 0.2 [10.8] 0.14
Percent of symptom-free days# 22.1 14.01 [30.0] 14.3 5.53 [30.4] 0.03
nP-value between groups at baseline in FEV1 percent predicted¼ 0.90.
#P-value between groups at baseline in symptom-free days¼ 0.37.
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compared to CFC-BDP ($977.05) (Po0:001). The
absolute median difference was $309, a 46%
increase compared to HFA-BDP.
Cost-effectiveness analysis
The cost-effectiveness analysis is presented in
Table 5. The cost of HFA-BDP was $4.07 per SFD.
For CFC-BDP, the cost per SFD was $8.86. In
economic analyses the true item of interest is the
incremental cost-effectiveness. The incremental
cost-effectiveness is the difference in costs for the
two therapies divided by the difference in effect.
This ratio provides the cost to obtain an additional
unit of effectiveness. The incremental cost-effec-
tiveness ratio was $5.77 (95% CI: $68.08 to
$4.08), indicating the HFA-BDP is a dominant
therapy (e.g., HFA-BDP is more effective and costs
less than CFC-BDP). Because the 95% CI was not
greater than zero, dominance by HFA-BDP was
consistent within the sample.
Sensitivity analysis
The primary analysis used median values for costs
and effects. If mean cost and mean effect are used
in place of the median values, the incremental
cost-effectiveness was $5.36. If the lower
strength of HFA-BDP was used for all patients, the
median total cost for patients on HFA-BDP was
$916.68. Therefore, the incremental cost-effec-
tiveness was $1.13 per SFD (95% CI $19.83 to
$4.38). To be consistent with other studies in
reporting the cost-effectiveness the primary ana-
lysis used annualized SFDs. Another method to
calculate the cost-effectiveness was to examine
the change in effect over time, accounting for
baseline values. When this was done, the incre-
mental cost-effectiveness ratio was $40.20, fa-
voring HFA-BDP.
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Table 3 Resource utilization for asthma exacer-
bations.
Item HFA-BDP (N ¼ 218) CFC-BDP (N ¼ 73) P-value
N % N %
Oral steroid bursts
None 180 82.6 57 78.1
One 30 13.7 13 17.8
Two 6 2.7 1 1.4
Three 1 0.5 2 2.7
Four 1 0.5 0 0.0 0.40
Hospitalizations for asthma
None 217 99.5 73 100.0
One 1 0.5 0 0.0 0.57
Urgent medical care visits
None 197 90.3 67 91.8
One 15 6.9 4 5.5
Two 5 2.3 0 0.0
Three 1 0.5 1 1.4
Four 0 0.0 1 1.4 0.74
Table 4 Cost estimates.
HFA-BDP CFC-BDP P-value
Median Mean [SD] Median Mean [SD]
Inhaled corticosteroids $379.89 $389.82 [151.57] $640.35 $658.33 [265.75] o0.001
Concomitant medications $189.72 $430.59 [557.63] $237.45 $420.19 [509.91] 0.83
Urgent care visits $0 $7.06 [23.73] $0 $8.28 [33.89] 0.74
Hospitalizations $0 $4.79 [70.8] $0 $0 [0] 0.57
Total costs $667.68 $891.35 [607.76] $977.05 $1173.95 [642.30] o0.001
Table 5 Cost-effectiveness in terms of symptom-free days.
HFA-BDP CFC-BDP Difference
Median total cost $667.68 $977.05 $309.37
Median symptom-free days per patient per year 163.9 110.3 53.6
Cost per symptom-free day $4.07 $8.86 $4.79
Incremental cost-effectiveness [95% confidence interval] $5.77 [$68.08 to $4.08]
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When the cost of an ED visit was used in place of
an office-based visit for all urgent care the median
total cost was $886 and $1149 for HFA-BDP and CFC-
BDP, respectively. The incremental cost-effective-
ness when using ED costs for urgent care visits was
$4.90. Changes in the cost of other components
at the extremes of the 95% confidence intervals had
little effect on the incremental cost-effectiveness,
mainly due to the cost of inhaled corticosteroids
and other concomitant medications accounting for
the majority of the costs.
Discussion
The results of this study suggest that HFA-BDP is
more cost-effective than conventional press and
breathe CFC-BDP. This is especially true when the
high strength of HFA-BDP is used. The incremental
cost-effectiveness ratio was $5.77, meaning that
use of HFA-BDP in place of CFC-BDP was more
effective but cost less. Using median values,
patients in this study reported more than 53
additional SFDs per year when receiving HFA-BDP
compared to those patients on CFC-BDP.
Safety and effectiveness analysis for the entire
473 patients enrolled in the trial found no
significant differences with respect to change in
predicted FEV1, adverse events, plasma cortisol, or
serum osteocalcin.14 Several studies have docu-
mented that HFA-BDP is equivalent at half the dose
of conventional CFC-BDP.18–20 Other trials have
found that HFA-BDP has equivalent efficacy as
fluticasone proprionate at a 1:1 ratio21,22 and
budesonide at a 1:2 ratio.23,24
The lack of significant difference between HFA-
and CFC-BDP in terms of FEV1, beta agonist use,
oral corticosteroids, urgent care visits, and hospi-
talizations was not completely surprising. Objec-
tive measures of lung function are only modestly
correlated with patient-reported measures, such as
asthma-related quality of life.25 In addition, pa-
tients that were enrolled in this study were on
stable doses of inhaled cortisteroids, suggesting
that asthma was well controlled. The lack of
significant differences in measures of exacerba-
tions, such as oral corticosteroid use, urgent
care visits, and hospitalizations, was probably
due to the low frequency of these events in
well-controlled populations. The selection of SFDs
as the outcomes in the analysis was done a priori
and according to recommendations of the
National Institutes of Health Heart, Lung, and
Blood Institute (NHBLI) working group on economic
studies in asthma.15 If the observed difference
in SFD was spurious, then the analysis would
resort to a cost-minization analysis, whereby one
would select the least expensive agent. In this
case, it would be HFA-BDP.
The relative benefits of ICS in the treatment of
asthma are well known. The National Heart, Lung,
and Blood Institute recommend ICS for all stages of
persistent asthma.2 Because of their prominent
place in therapy, it is no longer a question of
whether an ICS should be considered for patients
with persistent asthma, but which agent produces
the best desired clinical and economic benefits.
HFA-BDP is an extrafine aerosol that has been shown
to reach both small and large airways in higher
concentrations than conventional CFC-BDP, flutica-
sone, and triamcinolone.26 Based upon the analysis
in this report, it is likely that use of HFA-BDP may
be resource sparing when used in place of conven-
tional CFC-BDP.
Numerous prospective cost-effectiveness ana-
lyses of ICS have been conducted.5–13,27 In a Dutch
study, ICS plus scheduled short acting beta-agonists
were cost-effective for the treatment of asthma or
chronic obstructive pulmonary disease in adults
compared to scheduled short acting beta agonist
alone or with ipratropium bromide.8 ICS were also
found to be cost-effective relative to only short
acting beta-agonists in Dutch children with asth-
ma.7 Comparative cost-effective studies of ICS
agents conducted to date have been less informa-
tive because the economic evaluations are based
upon results from trials that have limited duration
(12 weeks or less).11–13,27 Because asthma is an
episodic condition that may fluctuate with the
allergy seasons, trials less than 1 year may fail to
capture an accurate assessment of resource con-
sumption and response to therapy.
Clinical and economic analyses must be inter-
preted within the context of the parameters of the
trial and analysis. This trial was conducted in an
unblinded fashion, in which both patients and
providers were aware of the study medications.
The lack of blinding may introduce bias that can
affect the results, especially with small sample
sizes. In addition, in usual practice patients and
providers are aware of the medications used. Thus,
the economic results from this study may be more
meaningful than those obtained from short dura-
tion, placebo controlled trials. In the primary
analysis the assumption was made that all patients
would be on the 80 mg strength of HFA-BDP and a
sensitivity analysis was performed assuming that
100% of patients were using the lower strength
product. In reality, some mix of the two products
will be used, although the market share equilibrium
is currently unknown. It should be noted that the
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cost per inhalation is greater with HFA-BDP than
CFC-BDP, but fewer doses of HFA-BDP are required
to achieve the same or better control. Thus, the
calculated costs were less when the higher strength
of HFA-BDP was used. It also follows that to the
extent that the higher strength product is used,
cost-effectiveness will more strongly favor HFA-
BDP. Another limitation with many ‘‘piggy-backed’’
economic evaluations is the inclusion of protocol-
induced resource consumption. Routine study visits
were not counted in the economic analysis but
urgent care visits associated with exacerbations
were. Also, patients may have been more closely
followed than typical clinical practice and devel-
opment of severe exacerbations may have been
avoided. In addition, patient adherence to medica-
tion consumption was monitored throughout the
study and may have led to atypically enhanced
patient compliance. All of these factors may affect
the results. The measure of SFDs was conducted as
periodic intervals then extrapolated over time. This
may have resulted in missing important events,
such as seasonal changes, that would affect the
results. However, patients were not enrolled
simultaneously and large numbers of persons were
enrolled into both groups, both of which are likely
to reduce any bias induced by having patients
complete symptom diaries on a periodic basis. The
perspective of this study was from a managed care
viewpoint and thus, indirect costs were not
included in the analysis. In addition, costs for MCOs
are likely to differ. Thus, the cost-effectiveness of
HFA-BDP will be influenced by the contractual
prices that MCOs negotiate with manufacturers.
In conclusion, switching patients to HFA-BDP in
place of CFC-BDP was found to be cost-effective,
resulting in significantly greater SFDs and signifi-
cantly less cost. These findings suggest HFA-BDP is a
dominant treatment and worthy of adoption by
health care payers in place of CFC-BDP.
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